Destiny Pharma PLC Destiny to present at UK-China AMR Workshop (2388V)
02 December 2019 - 6:00PM
UK Regulatory
TIDMDEST
RNS Number : 2388V
Destiny Pharma PLC
02 December 2019
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Destiny Pharma to present at the Partnerships to Tackle the
Global Challenge of AMR, UK-China AMR Workshop
Brighton, United Kingdom - 2 December 2019 - Destiny Pharma
(AIM: DEST), a clinical stage biotechnology company focused on the
development of novel antimicrobial drugs that address clear
commercial opportunities and also address the global problem of
antimicrobial resistance (AMR), announces that Daniel Hynes,
Director of Preclinical Development at Destiny Pharma, will present
on the progress of a two-year China-UK Industrial Research
programme researching novel antimicrobial candidates from the
Company's XF drug platform for use against dermal and ocular
infections at the Partnerships to Tackle the Global Challenge of
AMR, UK-China AMR Workshop on 3-5 December, 2019 in Beijing,
China.
Dr William Love, Chief Scientific Officer and Founder of Destiny
Pharma, commented:
"We are delighted to be part of this UK-China AMR programme and
to participate in this workshop with expert colleagues from China.
Destiny is focused on developing clinically and commercially
attractive new drugs that also address the serious global threat of
AMR. Currently our lead drug candidate, XF-73, is in an important
Phase 2b clinical study for the prevention of post-surgical
hospital infections and we look forward to reporting results in
mid-2020.
We are pleased with the progress we are making with our partners
in this grant funded project investigating the potential for XF
drugs to be used in new indications and look forward to reporting
further updates in 2020".
Destiny Pharma was awarded a significant grant funding up to
GBP1.6 million under a UK-China AMR programme in January 2019
researching novel antimicrobial candidates from the Company's XF
drug platform for use against dermal and ocular infections. This
collaboration with Cardiff University and Tianjin Medical
University aims to identify safe and efficacious compounds with a
reduced resistance profile.
The collaboration established under the UK-China AMR grant is
funded by Innovate UK and the Chinese Ministry of Science and
Technology.
About China-UK Industrial Research programme
The new China-UK Industrial Research programme seeks to extend
the knowledge base and activity profile of these novel drugs. This
will include study of multi-drug resistant (MDR), Gram negative and
positive, high priority bacterial pathogens in vitro, within
biofilms and within in vivo bacterial infection models. It will
also evaluate combining XF-drugs with existing antibiotics to
synergise and/or restore their efficacy against priority antibiotic
resistant bacteria. Data generated will help develop medicines that
address the growth of bacterial resistance either as a single drug
or restore efficacy of 'ineffective' antibiotics by combination
therapy. These new products represent a significant commercial
opportunity allowing the partners to expand investment in R&D
activities including an increased academic collaboration. In
addition, new combination drugs (incorporating a generic
antibiotic) could be competitively priced to enhance access to
effective, affordable drugs to healthcare service providers in low-
and middle-income countries, (LMICs).
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative
biotechnology company focused on the development and
commercialisation of novel medicines from its XF Platform that
represent a new approach to the treatment of infectious disease.
The company's lead programme is undergoing a Phase 2b clinical
trial and is targeting the prevention of post-surgical hospital
infections including MRSA. The XF drug candidates are being
developed for the prevention and treatment of life-threatening
infections caused by antibiotic-resistant bacteria, often referred
to as "superbugs". Tackling antimicrobial resistance has become a
global imperative recognised by the World Health Organisation (WHO)
and the United Nations, as well as the G7 and the G20 countries.
For further information, please visit
https://www.destinypharma.com
About XF-73
XF-73 is a synthetic antimicrobial active against all tested
Staphylococcus aureus strains, including drug--resistant strains.
By acting via a cell-surface mechanism it affects the bacterial
membrane permeability and integrity, leading to cell death. XF-73
has already been through seven successful Phase I/II clinical
trials showing it is safe and delivers a rapid antibacterial
action. In standard microbiology studies XF drugs have demonstrated
a unique no/low resistance profile that means that XF compounds
have the potential to deliver novel drugs that are clearly
differentiated from traditional antibiotics where resistance limits
their utility.
XF-73 is being studies for the prevention of post-surgical
staphylococcal infections. In the US, there are approximately 40
million surgeries per annum alone where the patient is at risk of a
post-surgical infection. However, within this large population
there are particular groups who are at an even higher risk of
infection due to the nature of their surgery or the procedures
and/or their specific hospital environment in which they are
treated. These higher risk surgical procedures include
cardiovascular, orthopaedic and other complex surgeries. Destiny
Pharma estimates that this totals approximately 14 million US
surgeries per year, with this figure set to rise within the context
of an ageing population.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCUAOKRKRAURAA
(END) Dow Jones Newswires
December 02, 2019 02:00 ET (07:00 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024